{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:16:59Z","timestamp":1768511819221,"version":"3.49.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2002,3,1]]},"DOI":"10.1038\/sj.mp.4001040","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:44:17Z","timestamp":1031251457000},"page":"247-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia"],"prefix":"10.1038","volume":"7","author":[{"given":"L","family":"Pani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G L","family":"Gessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,3,22]]},"reference":[{"key":"BF4001040_CR1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0010-440X(99)90082-2","volume":"40","author":"WW Shen","year":"1999","unstructured":"Shen WW . A history of antipsychotic drug development Compr Psychiatry 1999 40: 407\u2013414","journal-title":"Compr Psychiatry"},{"key":"BF4001040_CR2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF02245602","volume":"124","author":"BJ Kinon","year":"1996","unstructured":"Kinon BJ, Lieberman JA . Mechanisms of action of atypical antipsychotic drugs: a critical analysis Psychopharmacol (Berl) 1996 124: 2\u201334","journal-title":"Psychopharmacol (Berl)"},{"key":"BF4001040_CR3","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0920-9964(98)00158-3","volume":"35 Suppl","author":"RG Petty","year":"1999","unstructured":"Petty RG . Prolactin and antipsychotic medications: mechanism of action Schizophr Res 1999 35 Suppl: S67\u2013S73","journal-title":"Schizophr Res"},{"key":"BF4001040_CR4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1055\/s-2000-10037","volume":"68","author":"T Wetterling","year":"2000","unstructured":"Wetterling T . Weight gain from atypical neuroleptics\u2014an underreported adverse effect? Fortschr Neurol Psychiatr 2000 68: 546\u2013556","journal-title":"Fortschr Neurol Psychiatr"},{"key":"BF4001040_CR5","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 1999 156: 1686\u20131696","journal-title":"Am J Psychiatry"},{"key":"BF4001040_CR6","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","volume":"321","author":"J Geddes","year":"2000","unstructured":"Geddes J, Freemantle N, Harrison P, Bebbington P . Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 2000 321: 1371\u20131376","journal-title":"BMJ"},{"key":"BF4001040_CR7","first-page":"333","volume":"9","author":"T Hogberg","year":"1993","unstructured":"Hogberg T . The development of dopamine D2-receptor selective antagonists Drug Des Discov 1993 9: 333\u2013350","journal-title":"Drug Des Discov"},{"key":"BF4001040_CR8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1176\/appi.ajp.157.9.1379","volume":"157","author":"SG Siris","year":"2000","unstructured":"Siris SG . Depression in schizophrenia: perspective in the era of \u2018atypical\u2019 antipsychotic agents Am J Psychiatry 2000 157: 1379\u20131389","journal-title":"Am J Psychiatry"},{"key":"BF4001040_CR9","volume-title":"Dopamine and Mental Depression. Pergamon Press: Oxford","author":"GL Gessa","year":"1990","unstructured":"Gessa GL, Serra G (eds). Dopamine and Mental Depression. Pergamon Press: Oxford Adv in the Biosciences vol 77 1990"},{"key":"BF4001040_CR10","first-page":"1546","volume":"51","author":"RB Muller","year":"1975","unstructured":"Muller RB . Therapy of various forms of senile depressions with sulpirid (Dogmatil) Z Allgemeinmed 1975 51: 1546\u20131548","journal-title":"Z Allgemeinmed"},{"key":"BF4001040_CR11","first-page":"281","volume":"17","author":"P Niskanen","year":"1975","unstructured":"Niskanen P, Tamminen T, Viukari M . Sulpiride vs amitriptyline in the treatment of depression Curr Ther Res Clin Exp 1975 17: 281\u2013284","journal-title":"Curr Ther Res Clin Exp"},{"key":"BF4001040_CR12","first-page":"349","volume":"2","author":"I Pelc","year":"1976","unstructured":"Pelc I . Sulpiride and psychic decompensation Encephale 1976 2: 349\u2013361","journal-title":"Encephale"},{"key":"BF4001040_CR13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0024-3205(79)90573-3","volume":"25","author":"G Serra","year":"1979","unstructured":"Serra G, Argiolas A, Klimek V, Fadda F, Gessa GL . Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and locomotor activity Life Sci 1979 25: 415\u2013424","journal-title":"Life Sci"},{"key":"BF4001040_CR14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-8993(83)91125-3","volume":"264","author":"G Mereu","year":"1983","unstructured":"Mereu G, Casu M, Gessa GL . (-)-Sulpiride activates the firing rate and tyrosine hydroxylase activity of dopaminergic neurons in unanesthetized rats Brain Res 1983 264: 105\u2013110","journal-title":"Brain Res"},{"key":"BF4001040_CR15","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/00002826-199001001-00009","volume":"13 Suppl 1","author":"G Serra","year":"1990","unstructured":"Serra G, Forgione A, D'Aquila PS, Collu M, Fratta W, Gessa GL . Possible mechanism of antidepressant effect of L-sulpiride Clin Neuropharmacol 1990 13 Suppl 1: S76\u2013S83","journal-title":"Clin Neuropharmacol"},{"key":"BF4001040_CR16","unstructured":"Paizzis G . Italian Medical Dept. Sanofi\u2013Synth\u00e9labo. Data on file"},{"key":"BF4001040_CR17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0278-5846(94)90017-5","volume":"18","author":"T Tsukamoto","year":"1994","unstructured":"Tsukamoto T, Asakura M, Tsuneizumi T, Satoh Y, Shinozuka T, Hasegawa K . Therapeutic effects and side effects in patients with major depression treated with sulpiride once a day Prog Neuro-psychopharmacol Biol Psychiatr 1994 18: 615\u2013618","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatr"},{"key":"BF4001040_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0165-0327(97)00139-0","volume":"48","author":"E Smeraldi","year":"1998","unstructured":"Smeraldi E . Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study J Affect Disord 1998 48: 47\u201356","journal-title":"J Affect Disord"},{"key":"BF4001040_CR19","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1111\/j.1600-0447.1984.tb06858.x","volume":"69","author":"O Benkert","year":"1984","unstructured":"Benkert O, Holsboer F . Effect of sulpiride on endovenous depression Acta Psychiatr Scand 1984 69: 42S\u201348S","journal-title":"Acta Psychiatr Scand"},{"key":"BF4001040_CR20","first-page":"578","volume":"18","author":"A Elizur","year":"1975","unstructured":"Elizur A, Davison S . The evaluation of the anti-autistic activity of sulpiride Curr Ther Res 1975 18: 578\u2013584","journal-title":"Curr Ther Res"},{"key":"BF4001040_CR21","first-page":"593","volume":"144","author":"P Boyer","year":"1986","unstructured":"Boyer P . Efficacy of low doses of atypical neuroleptics (benzamides) in defect states Ann Med Psychol (Paris) 1986 144: 593\u2013599","journal-title":"Ann Med Psychol (Paris)"},{"key":"BF4001040_CR22","first-page":"457","volume":"15","author":"P Berner","year":"1989","unstructured":"Berner P, Kufferle B, Friedmann A, Grunberger J, Saletu B . Treatment of negative symptoms in schizophrenia with neuroleptics Encephale 1989 15: 457\u2013463","journal-title":"Encephale"},{"key":"BF4001040_CR23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.156.4.610","volume":"156","author":"JM Danion","year":"1999","unstructured":"Danion JM, Rein W, Fleurot O . Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group Am J Psychiatry 1999 156: 610\u2013616","journal-title":"Am J Psychiatry"},{"key":"BF4001040_CR24","first-page":"11","volume":"16","author":"C Lavilli","year":"1968","unstructured":"Lavilli C, Margarit J . The effect of sulpiride on the central nervous system Path Biol 1968 16: 11\u201314","journal-title":"Path Biol"},{"key":"BF4001040_CR25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1034\/j.1399-5618.2000.020307.x","volume":"2","author":"SN Ghaemi","year":"2000","unstructured":"Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK . Does olanzapine have antidepressant properties? A retrospective preliminary study Bipolar Disord 2000 2: 196\u2013199","journal-title":"Bipolar Disord"},{"key":"BF4001040_CR26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/0028-3908(81)90092-7","volume":"20","author":"MM Robertson","year":"1981","unstructured":"Robertson MM, Trimble MR . Neuroleptics as antidepressants Neuropharmacology 1981 20: 1335\u20131336","journal-title":"Neuropharmacology"},{"key":"BF4001040_CR27","first-page":"131","volume-title":"Treating Resistant Depression","author":"JC Nelson","year":"1987","unstructured":"Nelson JC . The use of antipsychotic drugs in the treatment of depression. In: Zohar J, Belmaker RH (eds) Treating Resistant Depression PMA Corp: New York 1987 131\u2013146"},{"key":"BF4001040_CR28","first-page":"1","volume":"60","author":"A Carlsson","year":"1993","unstructured":"Carlsson A . Thirty years of dopamine research Adv Neurol 1993 60: 1\u201310","journal-title":"Adv Neurol"},{"key":"BF4001040_CR29","first-page":"61","volume-title":"Brain Reward Systems and Abuse","author":"HC Fibiger","year":"1987","unstructured":"Fibiger HC, Phillips AG . Role of catecholamine transmitters in reward systems: implications for the neurobiology of affect In Oreland E. (ed) Brain Reward Systems and Abuse New York Press: New York 1987 pp 61\u201374"},{"key":"BF4001040_CR30","volume-title":"The brain and reward. In: Liebman J, Cooper SJ. (eds). The Neuropharmacological Basis of Reward","author":"RA Wise","year":"1989","unstructured":"Wise RA . The brain and reward. In: Liebman J, Cooper SJ. (eds). The Neuropharmacological Basis of Reward Oxford University Press: Oxford 1989"},{"key":"BF4001040_CR31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0301-0082(92)90018-A","volume":"39","author":"JR Blackburn","year":"1992","unstructured":"Blackburn JR, Pfaus JG, Phillips AG . Dopamine functions in appetitive and defensive behaviours Prog Neurobiol 1992 39: 247\u2013279","journal-title":"Prog Neurobiol"},{"key":"BF4001040_CR32","doi-asserted-by":"crossref","first-page":"RC29","DOI":"10.1523\/JNEUROSCI.19-19-j0003.1999","volume":"19","author":"S Ahn","year":"1999","unstructured":"Ahn S, Phillips AG . Dopaminergic correlates of sensory-specific satiety in the medial prefrontal cortex and nucleus accumbens of the rat J Neurosci 1999 19: RC29","journal-title":"J Neurosci"},{"key":"BF4001040_CR33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0165-0173(98)00019-8","volume":"28","author":"KC Berridge","year":"1998","unstructured":"Berridge KC, Robinson TE . What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 1998 28: 309\u2013369","journal-title":"Brain Res Rev"},{"key":"BF4001040_CR34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1523\/JNEUROSCI.17-02-00851.1997","volume":"17","author":"V Bassareo","year":"1997","unstructured":"Bassareo V, Di Chiara G . Differential influence of associative and nonassociative learning mechanisms on the responsiveness of prefrontal and accumbal dopamine transmission to food stimuli in rats fed ad libitum J Neurosci 1997 17: 851\u2013861","journal-title":"J Neurosci"},{"key":"BF4001040_CR35","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0006-3223(99)00236-X","volume":"46","author":"G Di Chiara","year":"1999","unstructured":"Di Chiara G, Loddo P, Tanda G . Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression Biol Psychiatry 1999 46: 1624\u20131633","journal-title":"Biol Psychiatry"},{"key":"BF4001040_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0014-2999(00)00566-5","volume":"405","author":"PS D'Aquila","year":"2000","unstructured":"D'Aquila PS, Collu M, Gessa GL, Serra G . The role of dopamine in the mechanism of action of antidepressant drugs Eur J Pharmacol 2000 405: 365\u2013373","journal-title":"Eur J Pharmacol"},{"key":"BF4001040_CR37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0014-2999(00)00565-3","volume":"405","author":"J Vetulani","year":"2000","unstructured":"Vetulani J, Nalepa I . Antidepressants: past, present and future Eur J Pharmacol 2000 405: 351\u2013363","journal-title":"Eur J Pharmacol"},{"key":"BF4001040_CR38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","volume":"20","author":"A Carlsson","year":"1963","unstructured":"Carlsson A, Lindquist M . Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain Acta Pharmacol Toxicol 1963 20: 140\u2013144","journal-title":"Acta Pharmacol Toxicol"},{"key":"BF4001040_CR39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archpsyc.1972.01750260021004","volume":"27","author":"SH Snyder","year":"1972","unstructured":"Snyder SH . Catecholamines in the brain as mediators of amphetamine psychosis Arch Gen Psychiatry 1972 27: 169\u2013179","journal-title":"Arch Gen Psychiatry"},{"key":"BF4001040_CR40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/archpsyc.1994.03950020040004","volume":"51","author":"J Hietala","year":"1994","unstructured":"Hietala J, Syv\u00e4lahti E, Vuorio K, Ngren K, Lehikoinen P, Ruotsalalainen U et al. Striatal D2-dopamine receptor characteristics inneuroleptic-naive schizophrenic patients studied with positronemission tomography Arch Gen Psychiatry 1994 51: 116\u2013123","journal-title":"Arch Gen Psychiatry"},{"key":"BF4001040_CR41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-9964(96)00102-8","volume":"23","author":"MH Dao-Costellana","year":"1997","unstructured":"Dao-Costellana MH, Paill\u00e8re-Martinot ML, Hantraye P, Attar-L\u00e9vy D, R\u00e9my P, Crouzel C et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients Schizophr Res 1997 23: 167\u2013174","journal-title":"Schizophr Res"},{"key":"BF4001040_CR42","doi-asserted-by":"crossref","unstructured":"Lindstr\u00f6m LH, Gefvert O, Hagberg G, Hagstr\u00f6m P, Lundberg T, Bergstr\u00f6m P et al. Increased synthesis of dopamine in prefrontal cortex and striatum in drug-naive schizophrenic patients studied by use of C11-labelled l-DOPA and positron emission tomography (PET) Proc Annu Meet ACNP, 36th 1997 p 290 (abstract)","DOI":"10.1016\/S0920-9964(97)88535-0"},{"key":"BF4001040_CR43","first-page":"237","volume":"41","author":"M Laruelle","year":"2000","unstructured":"Laruelle M . 2000 Imaging dopamine dysregulation in schizophrenia: implication for treatment Presented at Workshop Schizophr: Pathol Bases and Mech Antipsychotic Action, Chicago, quoted in Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML Interactions between monoamines, glutamate, and gaba in schizophrenia: new evidence Annu Rev Pharmacol Toxicol 2001 41: 237\u2013260","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BF4001040_CR44","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","volume":"93","author":"M Laruelle","year":"1996","unstructured":"Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects Proc Natl Acad Sci USA 1996 93: 9235\u20139240","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF4001040_CR45","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","volume":"94","author":"A Breier","year":"1997","unstructured":"Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method Proc Natl Acad Sci USA 1997 94: 2569\u20132574","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF4001040_CR46","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.11.1550","volume":"155","author":"A Abi-Dargham","year":"1998","unstructured":"Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Laruelle M et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort Am J Psychiatry 1998 155: 761\u2013767","journal-title":"Am J Psychiatry"},{"key":"BF4001040_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(91)90196-U","volume":"41","author":"AA Grace","year":"1991","unstructured":"Grace AA . Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia Neuroscience 1991 41: 1\u201324","journal-title":"Neuroscience"},{"key":"BF4001040_CR48","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","volume":"148","author":"KL Davis","year":"1991","unstructured":"Davis KL, Kahn RS, Ko G, Davidson M . Dopamine in schizophrenia: a review and reconceptualization Am J Psychiatry 1991 148: 1474\u20131486","journal-title":"Am J Psychiatry"},{"key":"BF4001040_CR49","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1096\/fasebj.6.7.1348713","volume":"6","author":"M Goldstein","year":"1992","unstructured":"Goldstein M, Deutch AY . Dopaminergic mechanisms in the pathogenesis of schizophrenia FASEB J 1992 6: 2413\u20132421","journal-title":"FASEB J"},{"key":"BF4001040_CR50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","volume":"1","author":"A Carlsson","year":"1988","unstructured":"Carlsson A . The current status of the dopamine hypothesis of schizophrenia Neuropsychopharmacology 1988 1: 179\u2013186","journal-title":"Neuropsychopharmacology"},{"key":"BF4001040_CR51","first-page":"379","volume-title":"Schizophrenia","author":"A Carlsson","year":"1995","unstructured":"Carlsson A . The dopamine theory revisited. In: Hirsch SR, Weinberger DR (eds) Schizophrenia Blackwell Science: Oxford 1995 379\u2013400"},{"key":"BF4001040_CR52","first-page":"61","volume":"36","author":"AY Deutch","year":"1992","unstructured":"Deutch AY . The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia J Neural Transm Suppl 1992 36: 61\u201389","journal-title":"J Neural Transm Suppl"},{"key":"BF4001040_CR53","first-page":"151","volume":"47","author":"A Fink-Jensen","year":"2000","unstructured":"Fink-Jensen A . Novel pharmacological approaches to the treatment of schizophrenia Dan Med Bull 2000 47: 151\u2013167","journal-title":"Dan Med Bull"},{"key":"BF4001040_CR54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF00229108","volume":"98","author":"RC Saunders","year":"1994","unstructured":"Saunders RC, Kolachana BS, Weinberger DR . Local pharmacological manipulation of extracellular dopamine levels in the dorsolateral prefrontal cortex and caudate nucleus in the rhesus monkey: an in vivo microdialysis study Exp Brain Res 1994 98: 44\u201352","journal-title":"Exp Brain Res"},{"key":"BF4001040_CR55","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","volume":"49","author":"L Farde","year":"1992","unstructured":"Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G . Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch Gen Psychiatry 1992 49: 538\u2013544","journal-title":"Arch Gen Psychiatry"},{"key":"BF4001040_CR56","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H . Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch Gen Psychiatry 1988 45: 789\u2013796","journal-title":"Arch Gen Psychiatry"},{"key":"BF4001040_CR57","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1471-4159.1990.tb01230.x","volume":"54","author":"B Moghaddam","year":"1990","unstructured":"Moghaddam B, Bunney BS . Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study J Neurochem 1990 54: 1755\u20131760","journal-title":"J Neurochem"},{"key":"BF4001040_CR58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0304-3940(94)90704-8","volume":"165","author":"KD Youngren","year":"1994","unstructured":"Youngren KD, Moghaddam B, Bunney BS, Roth RH . Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment Neurosci Lett 1994 165: 41\u201344","journal-title":"Neurosci Lett"},{"key":"BF4001040_CR59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D","volume":"24","author":"CR Ashby","year":"1996","unstructured":"Ashby CR, Wang RY . Pharmacological actions of the atypical antipsychotic drug clozapine: a review Synapse 1996 24: 349\u2013394","journal-title":"Synapse"},{"key":"BF4001040_CR60","first-page":"163","volume":"35","author":"ED Peselow","year":"1982","unstructured":"Peselow ED, Stanley M . Clinical trials of benzamides in psychiatry Adv Biochem Psychopharmacol 1982 35: 163\u2013194","journal-title":"Adv Biochem Psychopharmacol"},{"key":"BF4001040_CR61","first-page":"215","volume":"22","author":"A Pelissolo","year":"1996","unstructured":"Pelissolo A, Krebs MO, Olie JP . Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature Encephale 1996 22: 215\u2013219","journal-title":"Encephale"},{"key":"BF4001040_CR62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/106002809502900210","volume":"29","author":"CF Caley","year":"1995","unstructured":"Caley CF, Weber SS . Sulpiride: an antipsychotic with selective dopaminergic antagonist properties Ann Pharmacother 1995 29: 152\u2013160","journal-title":"Ann Pharmacother"},{"key":"BF4001040_CR63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0327(96)00103-6","volume":"43","author":"Y Lecrubier","year":"1997","unstructured":"Lecrubier Y, Boyer P, Turjanski S, Rein W . Amisulpride Study Group. Amisulpride versus imipramine and placebo in dysthymia and major depression J Affect Dis 1997 43: 95\u2013103","journal-title":"J Affect Dis"},{"key":"BF4001040_CR64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000026556","volume":"39","author":"P Boyer","year":"1999","unstructured":"Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O . Amisulpride versus amineptine and placebo for the treatment of dysthymia Neuropsychobiology 1999 39: 25\u201332","journal-title":"Neuropsychobiology"},{"key":"BF4001040_CR65","first-page":"1129","volume-title":"Psychopharmacology: The Third Generation of Progress","author":"CA Tamminga","year":"1987","unstructured":"Tamminga CA, Gerlach J . New neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress Raven Press: New York 1987 1129\u20131140"},{"key":"BF4001040_CR66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1471-4159.1975.tb11667.x","volume":"24","author":"A Tagliamonte","year":"1975","unstructured":"Tagliamonte A, De Montis G, Olianas M, Vargiu L, Corsini GU, Gessa GL . Selective increase of brain dopamine synthesis by sulpiride J Neurochem 1975 24: 707\u2013710","journal-title":"J Neurochem"},{"key":"BF4001040_CR67","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0014-2999(77)90301-6","volume":"44","author":"B Scatton","year":"1977","unstructured":"Scatton B, Bischoff S, Dedek J, Korf J . Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity Eur J Pharmacol 1977 44: 287\u2013292","journal-title":"Eur J Pharmacol"},{"key":"BF4001040_CR68","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1111\/j.1600-0447.1984.tb06860.x","volume":"69","author":"C Harnryd","year":"1984","unstructured":"Harnryd C, Bjerkenstedt L, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA . Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients Acta Psychiatr Scand 1984 69: S75\u2013S92","journal-title":"Acta Psychiatr Scand"},{"key":"BF4001040_CR69","first-page":"284","volume":"3","author":"MC Maubrey","year":"1988","unstructured":"Maubrey MC, Jacquot C, Gonidec J, Guez M, Idee JM, Margarit J . Profil pharmacologique et biochimique de l'amisulpride Ann Psychiatr 1988 3: 284\u2013297","journal-title":"Ann Psychiatr"},{"key":"BF4001040_CR70","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.2042-7158.1988.tb06306.x","volume":"40","author":"JK Chivers","year":"1988","unstructured":"Chivers JK, Gommeren W, Leysen JE, Jenner P, Marsden CD . Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors J Pharm Pharmacol 1988 40: 415\u2013421","journal-title":"J Pharm Pharmacol"},{"key":"BF4001040_CR71","doi-asserted-by":"crossref","first-page":"462A","DOI":"10.1097\/00002826-199201001-00241","volume":"15 (Suppl 1)","author":"SO Ogren","year":"1992","unstructured":"Ogren SO . Selective dopamine D2 receptor antagonists with an atypical neuroleptic profile Clin Neuropharmacol 1992 15 (Suppl 1): 462A\u2013463A","journal-title":"Clin Neuropharmacol"},{"key":"BF4001040_CR72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00004714-198706000-00007","volume":"7","author":"G Chouinard","year":"1987","unstructured":"Chouinard G . Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity J Clin Psychopharmacol 1987 7: 159\u2013164","journal-title":"J Clin Psychopharmacol"},{"key":"BF4001040_CR73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF00431718","volume":"86","author":"L Lindstrom","year":"1985","unstructured":"Lindstrom L, Besev G, Stening G, Widerlov E . An open study of remoxipride, a benzamide derivative, in schizophrenia Psychopharmacology 1985 86: 241\u2013243","journal-title":"Psychopharmacology"},{"key":"BF4001040_CR74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0447.1986.tb02659.x","volume":"73","author":"A Lund Laursen","year":"1986","unstructured":"Lund Laursen A, Gerlach J . Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity Acta Psychiatr Scand 1986 73: 17\u201321","journal-title":"Acta Psychiatr Scand"},{"key":"BF4001040_CR75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0447.1985.tb02585.x","volume":"72","author":"RG McCreadie","year":"1985","unstructured":"McCreadie RG, Morrison D, Eccleston D, Gall RG, Loudon J . An open multicentre study of the treatment of florid schizophrenia with remoxipride Acta Psychiatr Scand 1985 72: 139\u2013143","journal-title":"Acta Psychiatr Scand"},{"key":"BF4001040_CR76","volume-title":"Animal models of depressions: validity and application. In: Gessa GL (ed). Neurobiology Treatment","author":"P Willner","year":"1995","unstructured":"Willner P . Animal models of depressions: validity and application. In: Gessa GL (ed). Neurobiology Treatment Raven Press: New York 1995; pp 19\u201341"},{"key":"BF4001040_CR77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/026988110001400106","volume":"14","author":"M Papp","year":"2000","unstructured":"Papp M, Wieronska J . Antidepressant-like activity of amisulpride in two animal models of depression J Psychopharmacol 2000 14: 46\u201352","journal-title":"J Psychopharmacol"},{"key":"BF4001040_CR78","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0924-977X(00)00104-8","volume":"10","author":"F Drago","year":"2000","unstructured":"Drago F, Arezzi A, Virzi A . Effects of acute or chronic administration of substituted benzamides in experimental models of depression in rats Eur Neuropsychopharmacol 2000 10: 437\u2013442","journal-title":"Eur Neuropsychopharmacol"},{"key":"BF4001040_CR79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.pharmtox.41.1.237","volume":"41","author":"A Carlsson","year":"2001","unstructured":"Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML . Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence Annu Rev Pharmacol Toxicol 2001 41: 237\u2013260","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BF4001040_CR80","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0006-3223(97)00030-9","volume":"43","author":"AC Lahti","year":"1998","unstructured":"Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA . Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia Biol Psychiatry 1998 43: 2\u201311","journal-title":"Biol Psychiatry"},{"key":"BF4001040_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01249608","volume":"65","author":"K Svensson","year":"1986","unstructured":"Svensson K, Hjorth S, Clark D, Carlsson A, Wikstr\u00f6m H, Andersson B et al. (+)-UH 232 and (+)-UH 242: novel stereoselective DA receptor antagonists with preferential action on autoreceptors J Neural Transm 1986 65: 1\u201327","journal-title":"J Neural Transm"},{"key":"BF4001040_CR82","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1021\/jm00043a013","volume":"37","author":"C Sonesson","year":"1994","unstructured":"Sonesson C, Lin CH, Hansson L, Waters N, Svensson K, Carlsson A et al. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships J Med Chem 1994 37: 2735\u20132753","journal-title":"J Med Chem"},{"key":"BF4001040_CR83","volume-title":"Role of dopamine mechanisms in affective disorders. In: Meltzer HY (ed). Psychopharmacology: The Third Generation of Progress","author":"DC Jimerson","year":"1987","unstructured":"Jimerson DC . Role of dopamine mechanisms in affective disorders. In: Meltzer HY (ed). Psychopharmacology: The Third Generation of Progress Raven Press: New York 1987 pp 505\u2013511"},{"key":"BF4001040_CR84","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/026988119701100205","volume":"11","author":"MB Knable","year":"1997","unstructured":"Knable MB, Weinberger DR . Dopamine, the prefrontal cortex and schizophrenia J Psychopharmacol 1997 11: 123\u2013131","journal-title":"J Psychopharmacol"},{"key":"BF4001040_CR85","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","volume":"95","author":"JH Cha","year":"1998","unstructured":"Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene Proc Natl Acad Sci USA 1998 95: 6480\u20136485","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF4001040_CR86","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0959-4388(96)80079-1","volume":"6","author":"RA Wise","year":"1996","unstructured":"Wise RA . Neurobiology of addiction Curr Opin Neurobiol 1996 6: 243\u2013251","journal-title":"Curr Opin Neurobiol"},{"key":"BF4001040_CR87","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/brain\/111.2.299","volume":"111","author":"AM Gothham","year":"1988","unstructured":"Gothham AM, Brown RG, Marsden CD . \u2018Frontal\u2019 cognitive function in patients with Parkinson's disease \u2018on\u2019 and \u2018off\u2019 levodopa Brain 1988 111: 299\u2013321","journal-title":"Brain"},{"key":"BF4001040_CR88","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1176\/ajp.155.10.1325","volume":"155","author":"ND Volkow","year":"1998","unstructured":"Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals Am J Psychiatry 1998 155: 344\u2013349","journal-title":"Am J Psychiatry"},{"key":"BF4001040_CR89","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.112679","volume":"205","author":"T Brozoski","year":"1979","unstructured":"Brozoski T, Brown RM, Rosvold HE, Goldman PS . Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey Science 1979 205: 929\u2013932","journal-title":"Science"},{"key":"BF4001040_CR90","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1523\/JNEUROSCI.18-07-02720.1998","volume":"18","author":"U M\u00fcller","year":"1998","unstructured":"M\u00fcller U, von Cramon DY, Pollman S . D1- versus D2-receptor modulation of visuospatial working memory in humans J Neurosci 1998 18: 2720\u20132728","journal-title":"J Neurosci"},{"key":"BF4001040_CR91","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0165-0173(99)00045-4","volume":"31","author":"PS Goldman-Rakic","year":"2000","unstructured":"Goldman-Rakic PS, Muly EC III, Williams GV . D1 receptors in prefrontal cells and circuits Brain Res Rev 2000 31: 295\u2013301","journal-title":"Brain Res Rev"},{"key":"BF4001040_CR92","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.mp.4000904","volume":"6","author":"P Devoto","year":"2001","unstructured":"Devoto P, Flore G, Pani L, Gessa GL . Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex Mol Psychiatry 2001 6: 657\u2013664","journal-title":"Mol Psychiatry"},{"key":"BF4001040_CR93","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1073\/pnas.98.4.1964","volume":"98","author":"ZU Khan","year":"2001","unstructured":"Khan ZU, Koulen P, Rubinstein M, Grandy DK, Goldman-Rakic PS . An astroglia-linked dopamine D2-receptor action in prefrontal cortex Proc Natl Acad Sci USA 2001 98: 1964\u20131969","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF4001040_CR94","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0006-3223(99)00113-4","volume":"46","author":"LD Selemon","year":"1999","unstructured":"Selemon LD, Lidow MS, Goldman-Rakic PS . Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure Biol Psychiatry 1999 46: 161\u2013172","journal-title":"Biol Psychiatry"},{"key":"BF4001040_CR95","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0149-7634(99)00063-9","volume":"24","author":"D Vallone","year":"2000","unstructured":"Vallone D, Ricetti R, Borrelli E . Structure and function of dopamine receptors Neurosci Biobehav Rev 2000 24: 125\u2013132","journal-title":"Neurosci Biobehav Rev"},{"key":"BF4001040_CR96","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2165\/00003495-199040060-00008","volume":"40","author":"AN Wadworth","year":"1990","unstructured":"Wadworth AN, Heel RC . Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia Drugs 1990 40: 863\u2013879","journal-title":"Drugs"},{"key":"BF4001040_CR97","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/00004850-199705002-00006","volume":"12 Suppl 2","author":"B Scatton","year":"1997","unstructured":"Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ et al. Amisulpride: from animal pharmacology to therapeutic action Int Clin Psychopharmacol 1997 12 Suppl 2: S29\u2013S36","journal-title":"Int Clin Psychopharmacol"},{"key":"BF4001040_CR98","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.mp.4000336","volume":"3","author":"P Seeman","year":"1998","unstructured":"Seeman P, Tallerico T . Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors Mol Psychiatry 1998 3: 123\u2013134","journal-title":"Mol Psychiatry"},{"key":"BF4001040_CR99","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1523\/JNEUROSCI.10-07-02125.1990","volume":"10","author":"PS Goldman-Rakic","year":"1990","unstructured":"Goldman-Rakic PS, Lidow MS, Gallager DW . Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefronal cortex J Neurosci 1990 10: 2125\u20132138","journal-title":"J Neurosci"},{"key":"BF4001040_CR100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/0306-4522(91)90003-7","volume":"40","author":"MS Lidow","year":"1991","unstructured":"Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P . Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using 3H raclopride, 3H spiperone and 3H SCH23390 Neuroscience 1991 40: 657\u2013671","journal-title":"Neuroscience"},{"key":"BF4001040_CR101","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/385634a0","volume":"385","author":"Y Okubo","year":"1997","unstructured":"Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET Nature 1997 385: 634\u2013636","journal-title":"Nature"},{"key":"BF4001040_CR102","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0006-8993(90)91672-4","volume":"528","author":"J de Kuyser","year":"1990","unstructured":"de Kuyser J, de Backer JP, Vauquelin G, Ebinger G . The effect of aging on the D1 dopamine receptors in human frontal cortex Brain Res 1990 528: 308\u2013310","journal-title":"Brain Res"},{"key":"BF4001040_CR103","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF02244071","volume":"103","author":"T Suhara","year":"1991","unstructured":"Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T et al. Age-related changes in human D1 dopamine receptors measured by positron emission tomography Psychopharmacology 1991 103: 41\u201345","journal-title":"Psychopharmacology"},{"key":"BF4001040_CR104","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3758\/BF03210925","volume":"20","author":"TA Salthouse","year":"1992","unstructured":"Salthouse TA . Working-memory mediation of adult age differences in integrative reasoning Mem Cogn 1992 20: 413\u2013423","journal-title":"Mem Cogn"},{"key":"BF4001040_CR105","first-page":"627.6","volume":"25","author":"SA Castner","year":"1999","unstructured":"Castner SA, Goldman-Rakic PS . Profound cognitive impairments in non-human primates exposed to amphetamine Soc Neurosci Abstr 1999 25: 627.6","journal-title":"Soc Neurosci Abstr"},{"key":"BF4001040_CR106","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0165-6147(98)01186-9","volume":"19","author":"MS Lidow","year":"1998","unstructured":"Lidow MS, Williams GV, Goldman-Rakic PS . The cerebral cortex: a case for a common site of action of antipsychotics Trends Pharm Sci 1998 19: 136\u2013140","journal-title":"Trends Pharm Sci"},{"key":"BF4001040_CR107","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition American Psychiatric Association: Washington DC 1994 pp 276\u2013277"},{"key":"BF4001040_CR108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0165-0327(99)00056-7","volume":"56","author":"A Serretti","year":"1999","unstructured":"Serretti A, Jori MC, Casadei G, Ravizza L, Smeraldi E, Akiskal H . Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression J Affect Disord 1999 56: 17\u201325","journal-title":"J Affect Disord"},{"key":"BF4001040_CR109","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition American Psychiatric Association: Washington DC 1994 pp 345\u2013346"},{"key":"BF4001040_CR110","first-page":"12","volume":"61 Suppl 6","author":"BE Leonard","year":"2000","unstructured":"Leonard BE . Evidence for a biochemical lesion in depression J Clin Psychiatry 2000 61 Suppl 6: 12\u201317","journal-title":"J Clin Psychiatry"},{"key":"BF4001040_CR111","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/archpsyc.57.8.787","volume":"57","author":"G Lambert","year":"2000","unstructured":"Lambert G, Johansson M, Agren H, Friberg P . Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders Arch Gen Psychiatry 2000 57: 787\u2013793","journal-title":"Arch Gen Psychiatry"},{"key":"BF4001040_CR112","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-2999(96)00080-5","volume":"303","author":"\u00c5 Malmberg","year":"1996","unstructured":"Malmberg \u00c5, Jerning E, Mohell N . Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites Eur J Pharmacol 1996 303: 123\u2013128","journal-title":"Eur J Pharmacol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/4001040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4001040","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4001040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T22:27:19Z","timestamp":1682029639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/4001040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,1]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3,1]]}},"alternative-id":["BF4001040"],"URL":"https:\/\/doi.org\/10.1038\/sj.mp.4001040","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,1]]},"assertion":[{"value":"24 May 2001","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2001","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2001","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2002","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}